SG11201603063WA - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents
Compounds for use in prevention and treatment of neurodegenerative diseases and painInfo
- Publication number
- SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA
- Authority
- SG
- Singapore
- Prior art keywords
- pain
- prevention
- compounds
- treatment
- neurodegenerative diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| PCT/US2014/061734 WO2015061426A1 (fr) | 2013-10-23 | 2014-10-22 | Composés destinés à être utilisés dans la prévention et le traitement de maladies neurodégénératives et de la douleur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603063WA true SG11201603063WA (en) | 2016-05-30 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603063WA SG11201603063WA (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (fr) |
| EP (1) | EP3060566B1 (fr) |
| JP (1) | JP6534997B2 (fr) |
| KR (1) | KR102313314B1 (fr) |
| CN (1) | CN106414456B (fr) |
| AU (1) | AU2014340114B2 (fr) |
| BR (1) | BR112016008901B1 (fr) |
| CA (1) | CA2927699C (fr) |
| IL (1) | IL245103B (fr) |
| MX (1) | MX367707B (fr) |
| RU (1) | RU2695358C2 (fr) |
| SG (1) | SG11201603063WA (fr) |
| WO (1) | WO2015061426A1 (fr) |
| ZA (1) | ZA201603118B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792261A1 (ru) | 2015-05-29 | 2018-04-30 | Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити | Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы |
| US11753432B2 (en) | 2017-01-27 | 2023-09-12 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| AU2023219172A1 (en) * | 2022-02-10 | 2024-08-08 | Academia Sinica | Method of treating spinal cord injury and composition for use therein |
| WO2024010910A1 (fr) * | 2022-07-07 | 2024-01-11 | Academia Sinica | Méthode de traitement de la schizophrénie et composition à cet effet |
| WO2024145562A1 (fr) * | 2022-12-29 | 2024-07-04 | Academia Sinica | Méthodes de traitement de troubles du sommeil et composition destinée à être utilisée dans celui-ci |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003148A2 (fr) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Derives heteroaromatiques d'adenosine |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| ES2095960T3 (es) * | 1990-09-25 | 1997-03-01 | Rhone Poulenc Rorer Int | Compuestos que tienen propiedades antihipertensivas y antiisquemicas. |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| ES2645043T3 (es) * | 2009-11-13 | 2017-12-01 | Academia Sinica | Compuestos de doble acción que se dirigen al receptor A2A de adenosina y al transportador de adenosina para la prevención y el tratamiento de enfermedades neurodegenerativas |
| JP2013513551A (ja) * | 2009-12-10 | 2013-04-22 | 中国医学科学院葯物研究所 | Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠，抗うつ，抗痙攣，抗てんかん，抗パーキンソン病と認知証予防・治療の用途 |
| AU2013216773B2 (en) | 2012-02-09 | 2016-06-09 | Brandbumps, Llc | Decorative detectable warning panel having improved grip |
| US20150038445A1 (en) * | 2012-02-11 | 2015-02-05 | Academia Sinica | Methods and compositions for treating pain |
-
2014
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active IP Right Grant
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/fr active Application Filing
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 CA CA2927699A patent/CA2927699C/fr active Active
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/fr active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2695358C2 (ru) | 2019-07-23 |
| CN106414456A (zh) | 2017-02-15 |
| US10301348B2 (en) | 2019-05-28 |
| ZA201603118B (en) | 2019-04-24 |
| BR112016008901A2 (pt) | 2020-05-12 |
| AU2014340114B2 (en) | 2018-10-18 |
| CA2927699A1 (fr) | 2015-04-30 |
| EP3060566A4 (fr) | 2017-06-14 |
| AU2014340114A1 (en) | 2016-05-26 |
| CA2927699C (fr) | 2022-07-05 |
| KR102313314B1 (ko) | 2021-10-19 |
| US20160264613A1 (en) | 2016-09-15 |
| JP2016535019A (ja) | 2016-11-10 |
| KR20160086852A (ko) | 2016-07-20 |
| EP3060566B1 (fr) | 2018-09-05 |
| NZ719740A (en) | 2021-02-26 |
| JP6534997B2 (ja) | 2019-06-26 |
| MX2016005174A (es) | 2016-08-11 |
| IL245103B (en) | 2019-02-28 |
| WO2015061426A1 (fr) | 2015-04-30 |
| MX367707B (es) | 2019-09-03 |
| BR112016008901B1 (pt) | 2022-08-23 |
| EP3060566A1 (fr) | 2016-08-31 |
| RU2016118282A (ru) | 2017-11-28 |
| CN106414456B (zh) | 2018-12-14 |
| RU2016118282A3 (fr) | 2018-06-18 |
| IL245103A0 (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222530A1 (zh) | 用於皮膚處理的微閉合及相關方法 | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| HK1221178A1 (zh) | 卡博替尼劑型及其在癌症治療中的使用 | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| EP2836270A4 (fr) | Systèmes et procédés liés au traitement de la douleur dorsale | |
| EP2943189A4 (fr) | Procédés et compositions pour le traitement de maladies de démyélinisation | |
| HK1220352A1 (zh) | 和神經變性疾病的治療 | |
| ZA201603118B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
| EP2949651A4 (fr) | Benzothiazoles substitués et leurs appllications thérapeutiques pour le traitement de maladies humaines | |
| ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
| HK1222585A1 (zh) | 用於提供疼痛減輕和麻醉的二氫埃托啡 | |
| IL246036A0 (en) | A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| EP2962693A4 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer | |
| PL3598971T3 (pl) | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny | |
| EP2964227A4 (fr) | Traitement et prophylaxie de maladies rénales | |
| EP2986294A4 (fr) | Composés destinés au traitement de la douleur | |
| HK1218882A1 (zh) | 用於治療神經退化疾病和其它疾病的組合治療劑和方法 | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| ZA201506396B (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
| EP2986295A4 (fr) | Composés destinés au traitement de la douleur | |
| HUP1300454A2 (hu) | Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| EP2970152A4 (fr) | Préparation et procédé d'utilisation pour traiter des maladies respiratoires |